Agency for Science, Technology and Research

Geron Corporation

Genome Institute of Singapore

Lawrence W Stanton

Joseph D Gold

Simon McKenzie Cool

Victor Nurcombe

Ramkumar Mandalam

Ralph Brandenberger

Prasanna Ratnakar Kolatkar

John M Irving

Michael Mok

Manjiri M Bakre

Emily Li Chuan Tan

Irene Aksoy

Padmapriya Sathiyanathan

Rebekah M Samsonraj

Ralf Jauch

Prasanna R Kolatkar

A method for providing a sub-population of stem cell or plurality of stem cells by determining or modulating GSTT1 expression level or genotype is disclosed together with uses of the stem cells.

Stem cell subpopulations with differential GSTT1 expression or genotype

There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.

Mutant sox proteins and methods of inducing pluripotency

We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at least a portion of the time when the Wnt signalling pathway is activated.

Methods of specifying mesodermal, endodermal and mesoendodermal cell fates

The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN &#x3b1;-n1, IFN &#x3b1;-n3, human leukocyte IFN &#x3b1; or IFN &#x3b2;-1b.

Inhibition of SARS coronavirus infection with clinically approved antiviral drugs

This disclosure provides a system for qualifying embryonic stem cells intended for human therapy. A large-scale sequencing project has identified important markers that are characteristic of undifferentiated pluripotent cells. Combinations of these markers can be used to validate the self-renewing capacity of ES cells, and their ability to differentiate into tissue types suitable for regenerative medicine. The marker system of this invention has been used to screen feeder cells, media additives, and culture conditions that promote proliferation of stem cells without differentiation. A culture system optimized by following these markers is suitable for rapid expansion of undifferentiated cells from existing lines, or the derivation of new lines that are equally apposite for clinical use.

Marker system for preparing and characterizing high-quality human embryonic stem cells

Growing community of inventors

Singapore, Singapore

Lawrence W Stanton